A Recombinant Bispecific Single-Chain Fragment Variable Specific for HLA Class II and FcαRI (CD89) Recruits Polymorphonuclear Neutrophils for Efficient Lysis of Malignant B Lymphoid Cells
Explore this paper's citation graph
Summary
To the authors' knowledge, this is the first report of an FcαRI-directed bsscFv effectively recruiting PMNs for redirected cytotoxicity against human B cell malignancies and is an interesting candidate for further engineering of small, modular immunopharmaceuticals.
- Type
- article
- Published
- 2009-12-30
- Cited by
- 44
- References
- 42
- Access
- Open access
- OpenAlex
- https://openalex.org/W1915399895
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:207422199
Keywords
Cytotoxicity, Molecular biology, Human leukocyte antigen, Recombinant DNA, Single-chain variable fragment
References
- Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
- Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells1
- The kinetics of immune reconstitution after human marrow transplantation.
- Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity1
- HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.
- HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies.
- Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
- Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
- HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases.
- HLA class II antibodies in the treatment of hematologic malignancies.
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
- Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system.
- Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells
- Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies.
- Multiple roles for the major histocompatibility complex class I- related receptor FcRn.
- A recombinant bispecific single‐chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells
- NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
- Neutrophils in Anti-Cancer Immunological Strategies: Old Players in New Games
- From the bench to the bedside: ways to improve rituximab efficacy.
Cited by
- T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell
- Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells
- The state of antibody therapy.
- The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
- Novel Antibody-Based Proteins for Cancer Immunotherapy
- The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity
- Neutrophils as effector cells for antibody-based immunotherapy of cancer.
- Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection.
- Immunoglobulin A
- Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics
- The Fc‐alpha receptor is a new target antigen for immunotherapy of myeloid leukemia
- Distinct Functions of Neutrophil in Cancer and Its Regulation
- Exploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication
- Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16
- Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy
- Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo
- Evaluation of FcR-directed immunotherapeutic strategies to manipulate macrophages in in vitro and ex vivo models of chronic inflammation
- CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
- The regulation of pre-metastatic niche formation by neutrophils
- Monoclonal antibody‐mediated killing of tumour cells by neutrophils
Related papers
- Direct Binding of Monomeric Anti‐DNA Antibodies to Raji Cells
- Interpretation of the Raji cell assay in sera containing anti-nuclear antibodies and immune complexes.
- Cytotoxicity test of medical device with silver nanoparticles
- Inhibition effect of Disulfiram and combined with Cu on the proliferation and apopsis of Raji cells and its medchanism
- Synthesis and antitumor activity of aza-chalcones and their Pt(IV) complexes
- Inhibitory Effects of INF-α and Curcumin on the Proliferation of Raji Cells
- Protective effect of Cynomorii Herba extract on H_2O_2-induced cytotoxicity
- The Raji cell radioimmune assay for detecting immune complexes in human sera.
- Complement-dependent cellular cytotoxicity due to alternative pathway C3 activation by the target cell membrane.